Cencora (COR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$332.8B

Revenue (quarter)

$84.8B

Revenue growth (year over year)

+5.07%

Gross profit (trailing twelve months)

$13.2B

Gross margin

3.97%

Net income (trailing twelve months)

$2.6B

Net income (quarter)

$776.7M

Net income growth (year over year)

+12.60%

Net margin

0.79%

Return on equity

104.34%

EPS (trailing twelve months)

$13.53

Book value per share

$15.99

P/E (trailing twelve months)

24.78

Price to book

20.08

Debt to assets

96.13%

Payout ratio

27.42%

Dividend yield

0.71%

Company profile

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

• Is Cencora (COR) profitable?

  Yes. Cencora earned $2.6B in net income over the trailing twelve months, a net margin of 0.79%.

• How much revenue does Cencora (COR) make?

  Cencora generated $332.8B in revenue over the trailing twelve months, up 5.07% year over year.

• What is COR's P/E ratio?

  Cencora trades at 24.8 times trailing twelve-month earnings, on an EPS of $13.53.

• How do I buy stock in Cencora (COR)?

  COR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.